Abstract
Introduction Access to medical oxygen remains a challenge, with 60% of the world’s population lacking access to quality oxygen services. We explored whether ‘outsourced oxygen to the bedside’ (O2B), where private providers offer bundles of oxygen services, could be adopted and scaled across diverse health systems, to improve patient access to oxygen.
Methods Qualitative interviews were conducted with healthcare workers (HCWs), facility management staff and district medical officers in India, Nigeria, Tanzania, Kenya and Uganda, who had taken part in an O2B pilot. Interviews were conducted between 19th November 2024 and 25th January 2025, and explored the feasibility, fidelity, acceptability, perceived benefits and weaknesses of five O2B models. Analysis used a pragmatic codebook approach, with inductive and deductive coding, informed by implementation science frameworks.
Results We conducted 59 interviews, with managers and HCWs from 20 health facilities. We identified five themes relating to the potential for O2B pilots to be adopted within the health system: effect on oxygen culture, feasibility of whole of facility solutions, promotion of local ownership, being willing but unsure about the ability to pay, and the desire for hybrid tailored service models. HCWs and facility staff raised several positive factors within these themes but highlighted that understanding local facility needs and tailoring the services to embed within existing structures were important for sustainability.
Conclusion Overall, the O2B service approach shows potential for implementation beyond the pilots, but more understanding of how to optimize service delivery packages to different facility needs, while also prioritizing affordability is needed.
Competing Interest Statement
TB declares technical consultancies with UNICEF, the World Bank, USAID, and PATH, and is Board member of the non-profit organisation EECC Global, all outside the submitted work. HG has provided unpaid technical advice on oxygen therapy to FREO2 Foundation (one of the O2B providers).
Funding Statement
The research was funded by Brink through a grant from the UK FCDO. The views expressed in this report are those of the authors. This material has been funded by UK International Development as a part of the Oxygen CoLab; however, the views expressed do not necessarily reflect the UK governments official policies, nor those of any of the individuals and organisations referred to in the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approvals were obtained from ethical review boards in each country: Monk Prayogshala Institutional Review Board, India (reference: #156-024); Maseno University Scientific and Ethics Review Committee, Kenya (reference: MSU/DRPI/MUSERC/01361/23); National Commission for Science, Technology and Innovation, National Commission for Science, Technology and Innovation, Kenya (license number: NACOSTI/P/24/37427, reference: #673262); Health Research and Ethics Committee, LASUTH, Lagos State, Nigeria (reference: LREC/06/10/2498); Health Research Ethics Committee, Ogun State, Nigeria (reference: OGHREC/467/2024/290/APP); National Institute for Medical Research, Tanzania (reference: NIMR/HQ/R.8a/Vol.IX/4743); Ugandan National Council for Science and Technology, Uganda (reference: HS5437ES); Makerere University School of Health Sciences REC, Uganda(reference: MAKSHSREC-2023-600). Approval was granted by the Swedish Ethics Review Authority for the processing of personal data (reference: DNR 2024-00868-01).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Given the qualitative nature of the data, transcripts cannot be sufficiently anonymised for Open Data Access. Data can be requested for the purposes of further academic research, by contacting Carina King (carina.king{at}ki.se) and Freddy Eric Kitutu (kitutufred{at}gmail.com). Requests will be reviewed and discussed with the site qualitative leads, and approval from local ethical committees will need to be sought.
